GlobeNewswire

2024-10-08 14:35

Boehringer receives U.S. FDA Breakthrough Therapy designation and initiates two phase III trials in MASH for survodutide

  • The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on survodutide’s groundbreaking results from Phase II  study1
  • Boehringer launches two Phase III studies of survodutide, LIVERAGE in adults with MASH and moderate or advanced fibrosis, and LIVERAGE-Cirrhosis in those with MASH and cirrhosis

Boehringer Ingelheim announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for survodutide (BI 456906), a dual glucagon/GLP-1 receptor agonist2 for the treatment of adults living with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis (stages 2 or 3). The Breakthrough Therapy designation expedites the development and review of medicines for serious or life-threatening diseases that have shown preliminary clinical evidence indicating substantial improvement over available treatments.3 

In addition, Boehringer announced the initiation of two Phase III clinical trials for survodutide for the treatment of adults living with MASH and fibrosis (scarring).

LIVERAGE will examine whether survodutide can improve MASH and/or fibrosis after 52 weeks of treatment and reduce the risk of end-stage liver disease outcomes after approximately seven years of treatment in adults living with MASH and moderate or advanced liver fibrosis (stages 2 or 3). LIVERAGE-Cirrhosis will examine whether survodutide can reduce the risk of end-stage liver disease outcomes after approximately four and a half years of treatment in adults living with MASH and compensated cirrhosis (fibrosis stage 4), a condition where the liver presents severe scarring.4

“Given the significant burden of MASH and the limited therapeutic options, novel approaches are urgently needed,” said Dr. Arun Sanyal, M.D., Professor of Medicine at Virginia Commonwealth University School of Medicine and Director of VCU’s Stravitz-Sanyal Institute for Liver Disease and Metabolic Health. “The Phase III LIVERAGE studies represent an exciting opportunity to investigate whether survodutide, with its dual glucagon and GLP-1 receptor agonist mechanism of action, can help address this significant medical need.”

"With the number of MASH patients expected to rise worldwide in the coming years, advancing our understanding of this condition is more crucial than ever," said Shashank Deshpande, Head of Human Pharma at Boehringer Ingelheim. "Our Phase III trial program with survodutide is one of the largest of its kind in terms of countries and sites involved. Notably, the program’s innovative design, which specifically targets advanced fibrosis including patients living with cirrhosis due to MASH – the most in-need population, is set to redefine the treatment landscape. The Breakthrough Therapy designation underscores that this potential best-in-class therapy has an opportunity to fundamentally change how MASH is treated." 

Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally. Zealand has a co-promotion right in the Nordic countries.

About LIVERAGE and LIVERAGE-Cirrhosis

LIVERAGE and LIVERAGE-Cirrhosis are global Phase III clinical trials investigating the efficacy and safety of survodutide in adults with MASH and fibrosis stages 2 or 3 and in those with compensated MASH cirrhosis (stage 4), respectively. LIVERAGE will enroll approximately 1,800 adults, and LIVERAGE-Cirrhosis will enroll approximately 1,590 adults. In each trial, participants will be randomized to receive weekly injections of either survodutide, reaching a maximum dose of 6 mg, or placebo.

LIVERAGE consists of two parts. The two primary endpoints of part one are proportion of patients achieving MASH resolution without worsening of fibrosis, and at least a 1-point improvement in fibrosis without worsening of MASH, after 52 weeks of treatment. The primary endpoint of part two, which will continue for approximately seven years, is time to first occurrence of liver-related events or all-cause mortality.

The primary endpoint of LIVERAGE-Cirrhosis, which will continue for approximately four and a half years, is the time to first occurrence of all-cause mortality or liver-related events.

About survodutide (BI 456906)

Survodutide is a glucagon/GLP-1 receptor dual agonist that activates both the glucagon and GLP-1 receptors, which play a role in controlling metabolic functions.2 Survodutide is being evaluated in a robust Phase III clinical development program, including the LIVERAGE studies for people living with MASH and fibrosis and the SYNCHRONIZE studies for people living with overweight or obesity.5,6,7,8 

Survodutide’s potential to treat adults with non-cirrhotic MASH and moderate or advanced fibrosis (stages 2 or 3) has been recognized by the U.S. FDA, which granted it:

  • Fast Track designation in May 20219 and;
  • Breakthrough Therapy designation in September 2024.

Survodutide’s potential to treat adults with MASH and fibrosis has also been recognized by:

  • the European Medicines Agency (EMA), through acceptance to its PRIME scheme in November 202310 and;
  • the Center for Drug Evaluation of China’s National Medical Products Administration (NMPA), which granted it Breakthrough Therapy designation in June 2024.

Survodutide is licensed to Boehringer Ingelheim from Zealand Pharma, with Boehringer solely responsible for development and commercialization globally. Zealand has a co-promotion right in the Nordic countries. Survodutide is part of Boehringer Ingelheim’s research and development portfolio in the cardiovascular, renal and metabolic disease areas. 

About metabolic dysfunction-associated steatohepatitis (MASH) 

MASH is a chronic and progressive liver disease caused by a build-up of fat in the liver,11,12 and is a more severe form of metabolic dysfunction-associated steatotic liver disease (MASLD).13 In the U.S., cases of MASH are predicted to rise by 63% between 2015 and 2030, from 16.5 million to 27.0 million cases.14 MASH is a disease closely associated with interconnected cardiovascular, renal and metabolic conditions,15,16 and it is estimated that 34% of people living with obesity also have MASH.17

MASH severity is assessed using a scale that ranges from F0 to F4, which measures the level of fibrosis (scarring):18

  • 0-1: indicates no or mild fibrosis 
  • 2-3: indicates moderate or advanced fibrosis
  • 4: indicates cirrhosis

About Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com

Boehringer Ingelheim’s Intended Audiences Notice

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Media contacts

Harro Ten Wolde
Email: harro.ten_wolde@boehringer-ingelheim.com
Phone: +49 (6132) 77-181352

Jennifer Forsyth
Email: jennifer.forsyth@boehringer-ingelheim.com
Phone: +1 (203) 791-5889

References

1Sanyal AJ, Bedossa P, Fraessdorf M, et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. N Engl J Med. 2024;391(4):311-319.

2Zimmermann T, Thomas L, Baader-Pagler T, et al. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy. Mol Metab. 2022;66:101633.

3U.S. Food & Drug Administration. Breakthrough Therapy. Available at: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy. Accessed September 2024.

4Kumar R, Kumar S, Prakash SS. Compensated liver cirrhosis: Natural course and disease-modifying strategies. World J Methodol. 2023;13(4):179-193.

5Boehringer Ingelheim. Phase III studies to investigate survodutide for people living with obesity and overweight, with and without diabetes, cardiovascular disease and chronic kidney disease. Available at: www.boehringer-ingelheim.com/phase-3-studies-survodutide-obesity-and-overweight. Accessed September 2024.

6Clinicaltrials.gov. A Study to Test Whether BI 456906 Helps Chinese People Living With Overweight or Obesity to Lose Weight. Available at: clinicaltrials.gov/study/NCT06214741. Accessed September 2024.

7Clinicaltrials.gov. A Study to Test Whether BI 456906 Helps Japanese People Living With Obesity Disease (SYNCHRONIZE™JP). Available at: clinicaltrials.gov/study/NCT06176365. Accessed September 2024.

8Clinicaltrials.gov. A Study to Test Whether Survodutide Helps People Living With Obesity or Overweight and With a Confirmed or Presumed Liver Disease Called Non-alcoholic Steatohepatitis (NASH) to Reduce Liver Fat and to Lose Weight. Available at: https://clinicaltrials.gov/study/NCT06309992. Accessed September 2024.

9Boehringer Ingelheim. Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH. Available at: www.boehringer-ingelheim.com/us/press-release/boehringer-ingelheim-and-zealand-pharma-receive-fda-fast-track-designation. Accessed September 2024.

10European Medicines Agency. List of medicines currently in PRIME scheme. Available at: www.ema.europa.eu/en/documents/other/list-medicines-currently-prime-scheme_en.xlsx. Accessed September 2024.

11Ramai D, Facciorusso A, Vigandt E, et al. Progressive Liver Fibrosis in Non-Alcoholic Fatty Liver Disease. Cells. 2021;10(12):3401.

12National Institute of Diabetes and Digestive and Kidney Diseases. Nonalcoholic Fatty Liver Disease (NAFLD) and NASH. Available at: www.niddk.nih.gov/health-information/liver-disease/nafld-nash. Accessed September 2024

13American Liver Foundation. Nonalcoholic steatohepatitis (NASH): Symptoms & complications (2023). Available at: liverfoundation.org/liver-diseases/fatty-liver-disease/nonalcoholic-steatohepatitis-nash/. Accessed September 2024.

14Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018;67(1):123-133.

15Musso, Giovanni, et al. “Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.” PLoS Medicine. Vol. 11, no. 7, July 2014, p. E1001680. doi: 10.1371/journal.pmed.1001680.

16Schnell. Oliver, et al. “CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes.” Cardiovascular Diabetology. Vol. 23, no. 1, Mar. 2024. doi: 10.1186/s12933-024-02180-8.

17Quek J, Chan KE, Wong ZY, et al. Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2023;8(1):20-30.

18Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313-1321.




Primary Logo

source: Boehringer Ingelheim

【香港好去處】2025去邊最好玩?etnet為你提供全港最齊盛事活動,所有資訊盡在掌握!► 即睇

人氣文章
最近7天
1
高息定存 | 6個月港元定存3.8厘新高,188日快閃優惠3.68厘
2
高息定存 | 富邦推快閃定存優惠3個月3.9厘,華僑188日3.68厘
3
港股 | 蕭猷華:恒指料退守至18600點,宜逢低吸納
4
內銀股 | 人行再提擇機減息降準,內銀獲中金唱好,應該點部署?
5
大國博弈 | 【FOCUS】騰訊商湯寧德重挫,CMC清單劍指軍民融合
6
新股掛牌 | 布魯可首日掛牌升41%,每手賺7395元
7
加州山火 | 【FOCUS】洛杉磯烈火焚城,天災背後藏人禍
8
高息定存 | 一周高息合集,恒生1個月定存4厘,工銀亞洲3個月最高5厘
9
高息定存 | 渣打特選客6個月3.48厘,建行亞洲推1個月6.18厘高息吸客
10
高息定存 | 一周高息合集,銀行高息搶存,富邦1個月4.88厘,華僑1年期3.6厘
11
高息定存 | 花旗3個月港元定存息加至4厘,信銀國際3.88厘
12
英偉達 | DeepSeek衝擊AI晶片行業結構 英偉達暴跌仍未急抄底
13
一本萬利 | 2025年的五個「勿」(有片)
14
互聯支付 | 黃俊碩:轉數快與IBPS互聯支付所產生的發展契機
15
環球央行 | 歐洲央行宣布再次減息0.25厘,符合市場預期
16
高息定存 | 一周高息合集,銀行高息吸客,低門檻10萬享6.18厘,3個月最高5厘
17
港股 | 蕭猷華:恒指春節前目標21500點
18
專訪|洪灝:美股更大跌幅在前面,恐需習慣4%通脹(有片)
19
神州經脈 | 基金賣股票據報受限,滬指連跌四日,人行穩匯率
20
財政預算案2025 | 羅兵咸料本財年財赤948億,財政儲備降至紀錄新低
21
習近平應約與特朗普通電話,特:冀盡快與習見面
22
加州山火 | 美國洛杉磯大火失控,被迫撤離人數增至18萬
23
【FOCUS】去年貿易順差破紀錄,中國擴消費增緊迫感
24
【FOCUS】侵侵就職倒數一周,美元及油價劇本臨揭盅
25
高息定存 | 一周高息合集,部分銀行逆市加息,南商3個月加至3.8厘
26
賣地計劃 | 政府今季推一幅東涌住宅地涉745伙,全年供應不達標
27
加州山火造成超500億美元損失,大量房主未買保險
28
雷賢達觀點 | 香港篇:恒指年波幅料六千點,港須全面融入大灣區
29
新世界 | 摩通:新世界若債務違約或打開行業「潘朵拉盒子」
30
新股上市 | 布魯可傳延遲上市,港交所:FINI顯示有誤,續按上市時間表進行
專業版
HV2
精裝版
SV2
串流版
IQ 登入
強化版
TQ
強化版
MQ

【etnet 30周年】多重慶祝活動一浪接一浪,好禮連環賞!

【蛇年行大運 新年好賞「飾」】etnet賞太歲開運趨吉避凶神器

etnet榮獲HKEX Awards 2023 「最佳證券數據供應商」大獎

大國博弈

貨幣攻略

說說心理話

聖誕新年特輯

Watch Trends 2024

北上食買玩

Art Month 2024

秋天養生食療

山今養生智慧

輕鬆護老